Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335068 | 0.83 | AOC3 (0.40) | AOC3TAAR1OPRK1 | |
| SCHEMBL335051 | 0.82 | AOC3 (0.41) | AOC3SLC6A2SLC6A4TAAR1OPRK1 | |
| SCHEMBL1132949 | 0.82 | OPRK1 (0.53) | TAAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL335015 | 0.81 | PNMT (0.49) | SLC6A2SLC6A4TAAR1OPRK1IDO1 | |
| SCHEMBL334729 | 0.81 | ROCK1 (0.39) | AOC3SLC6A2SLC6A4TAAR1IDO1 | |
| Hydrochloric Acid SCHEMBL31500336 | 0.81 | AOC3 (0.40) | AOC3SLC6A2SLC6A4TAAR1OPRK1 | |
| SCHEMBL334856 | 0.81 | GBA1 (0.36) | SLC6A2SLC6A4OPRK1 | |
| Hydrochloric Acid SCHEMBL30606596 | 0.81 | AOC3 (0.40) | AOC3SLC6A2SLC6A4TAAR1OPRK1 | |
| Hydrochloric Acid SCHEMBL26598986 | 0.81 | AOC3 (0.40) | AOC3SLC6A2SLC6A4TAAR1OPRK1 | |
| Hydrochloric Acid SCHEMBL26598980 | 0.81 | AOC3 (0.40) | AOC3SLC6A2SLC6A4TAAR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | AOC3 4508/4885SLC6A2 4677/4885SLC6A4 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.